Q-omics provides the consensus-scored RNY4P23 profile across patient tissues and cancer cell-line models. RNY4P23 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RNY4P23 is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, RNY4P23 RNA expression shows 11,501 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight LIHC, BRCA, and LUAD as cancer lineages where RNY4P23 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNY4P23 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNY4P23 survival associations across molecular data types. RNY4P23 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNY4P23 RNA expression–survival associations across cancer types. High RNY4P23 expression shows unfavorable associations in LIHC, PAAD, ACC, UVM, DLBC and LUAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for RNY4P23 RNA expression.
This table summarizes RNY4P23 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNY4P23. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNY4P23 shows higher tumor expression in BRCA, STAD, LUAD and HNSC. The BRCA box plot shows higher RNY4P23 RNA expression in tumor versus normal tissue (log2 FC = +0.131, t-test p = .004).
This table shows molecular features associated with RNY4P23 in patient tissues and cancer cell lines. In patient samples, RNY4P23 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set.
